Clinical TrialCompleted

A Low-Dose Ketamine Infusion for Acute and Maintenance Treatment for Severe Depression and Suicide: A Double-Blind Randomized Controlled Study

Parallel randomized double-blind trial of IV ketamine 0.5 mg/kg vs midazolam 0.045 mg/kg (active placebo) for acute and maintenance treatment of severe depression with suicidal ideation in adults 20–65. Target enrollment: 48. Primary outcome: rate of reduction in suicide symptoms post-infusion. Conducted at Cheng Hsin General Hospital, Taipei, Taiwan.

Ask Blossom about this trial
Target Enrollment
48 participants
Study Type
interventional
Design
Randomized, double Blind

Study Protocol, Arms & Participants

Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.

See Pro Plans

Study Details

  • Status
    Completed
  • Type
    interventional
  • Design
    Randomizeddouble Blind
  • Target Enrollment48 participants
  • Timeline
    Start: 2018-09-01

Related Publications

PaywallindividualPooled analysis

A pilot randomized controlled trial of ketamine in Borderline Personality Disorder

This randomised controlled trial (n=22) is the first to study ketamine (35mg/70kg) in Borderline (BPD) in a placebo-controlled study. The study didn't report statistically significant differences between the ketamine and midazolam (active placebo) groups, though it did show a positive trend.

Published
Journal
Neuropsychopharmacology
Authors
Fineberg, S. K., Choi, E. Y., Shapiro-Thompson, R., Dhaliwal, K., Neustadter, E., Sakheim, M., Null, K., Trujillo-Diaz, D., Rondeau, J., Pittaro, G. F., Peters, J. R., Corlett, P. R., Krystal, J. H.

Your Personal Research Library

Go Pro to save trials, add notes, rate research, and organize custom shelves.

See Pro Plans